New Zealand markets open in 8 hours 9 minutes

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9100-0.0700 (-3.54%)
At close: 04:00PM EDT
1.9400 +0.03 (+1.57%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.9800
Open1.9700
Bid1.9000 x 7600
Ask1.9300 x 7600
Day's range1.8601 - 2.0250
52-week range0.3450 - 2.1050
Volume6,433,531
Avg. volume10,344,157
Market cap491.496M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

    MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life. "The completion of dosing for Cohort 2 p

  • GlobeNewswire

    Ocugen Provides Business Update with First Quarter 2024 Financial Results

    Conference Call and Webcast Today at 8:30 a.m. ETAll three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market Authorization Application (MAA) approval targets MALVERN, Pa., May 14, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell thera

  • GlobeNewswire

    Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

    MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on Ma